T Cell Therapy Market Analysis Report - Size & Share 2030
[研究报告] 2022年T细胞治疗市场规模价值27.54亿美元，预计到2030年将达到90.3501亿美元。预计2022-2030年期间的复合年增长率为16.0%。
市场洞察和分析师观点：
最有前景的癌症治疗方法之一是嵌合抗原受体 (CAR) T 细胞疗法，每年都有越来越多的临床前和临床研究开展，以扩大其应用范围。CAR T 细胞疗法也引起了肿瘤学家和学者的兴趣。尽管 CAR T 细胞疗法显示出同样的能力，可以摧毁极晚期白血病和淋巴瘤，并能使疾病持续多年，但免疫检查点抑制剂比 CAR T 细胞疗法更常见、应用更广泛。预计医院将广泛采用 CAR-T 细胞疗法；然而，为了提供这种疗法，制造和医疗领域必须建立一个生态系统，用于收集原材料、加工产品、分配产品和监测患者。由于全球癌症负担不断加重，以及 T 细胞疗法获批数量不断增加，对 T 细胞疗法的需求不断增长。
在T 细胞治疗市场运营的公司专注于战略发展，例如合作、协议和投资，以提高销售额、扩大地理覆盖范围并增强满足现有客户群更大需求的能力。例如，2023 年 8 月，安斯泰来向 Poseida 的 CAR T 细胞疗法投资了 5000 万美元。作为协议的一部分，安斯泰来将对 P-MUC1C-ALLO1 在实体瘤中的许可拥有独家谈判权和优先购买权。
增长动力和挑战：
根据世界卫生组织 (WHO) 的数据，2020 年，癌症是全球主要死亡原因，导致约 1000 万人死亡。根据国际癌症研究机构的数据，到 2040 年，全球癌症负担将增加 3020 万例新病例。嵌合抗原受体 (CAR) T 细胞疗法可以潜在地治疗一种利用免疫系统对抗癌症的新型癌症治疗方法。CAR T 细胞是一种创新药物，由于其成功的临床结果而获得 FDA 的批准，它已经扭转了治疗血液系统恶性肿瘤的局面，例如弥漫性大 B 细胞淋巴瘤 (DLBCL) 和 B 细胞急性淋巴细胞白血病 (B-ALL)。根据白血病和淋巴瘤协会的数据，在美国，每 3 分钟大约有一人被诊断出患有白血病、淋巴瘤或骨髓瘤。到 2023 年，预计美国将有近 180,000 人被诊断出患有淋巴瘤和白血病。DLBCL) and B-cell acute lymphoblastic leukemia (B-ALL) by achieving approval from the FDA based on their successful clinical outcomes. According to the Leukemia & Lymphoma Society, around one person every 3 minutes in the US is diagnosed with leukemia, myeloma. In 2023, nearly 180,000 people in the US are expected to be diagnosed with lymphoma and leukemia.
T 细胞技术因其较高的成功率而经常用于癌症免疫治疗。2021 年，Labiotech.eu（欧洲生物技术行业领先的在线媒体）表示，全球正在进行 500 多项用于癌症治疗的 CAR T 细胞临床试验。大多数在东亚、美国和欧洲进行。因此，日益加重的癌症负担正在推动 T 细胞治疗市场的增长。immunotherapy due to their higher success rate. In 2021, Labiotech.eu (a leading online media for the European biotech industry) stated that more than 500 CAR T cells clinical trials for cancer treatment are being carried out globally. Most are being carried out in East Asia, the US, and Europe. Thus, the growing burden of cancer is driving the T cell therapy market growth.
由于 CAR T 细胞疗法很复杂，因此会产生一些高风险的副作用。CAR T 细胞疗法引起的最常见和最严重的副作用之一是细胞因子释放综合征 (CRS)。CAR T 细胞疗法的其他副作用是神经系统影响，包括严重的意识模糊、癫痫样活动和言语障碍。神经毒性是大多数抗 CD19 CAR T 细胞疗法患者的副作用。ICANS 是 CAR T 细胞疗法的常见且具有挑战性的不良反应，25-44% 的血液系统恶性肿瘤儿童会出现这种不良反应。ICANS 通常在 CAR T 细胞输注后 7-10 天内发生，有时长达 3 周，并且可以同时发生或在 CRS 后不久发生。因此，治疗副作用的挑战限制了 T 细胞疗法市场的增长。 cytokine release syndrome (CRS). The other side effects of CAR T cell therapies are neurologic effects, including severe confusion, seizure-like activity, and impaired speech. Neurotoxicity is a side effect in most anti-CD19 CAR T cell therapy patients. ICANS is a common and challenging adverse effect of CAR T cell therapy, which occurs in 25–44% of children with hematologic malignancies. ICANS usually occurs within 7–10 days, sometimes up to 3 weeks after CAR T cell infusion and can occur concurrently or shortly after CRS. Thus, the challenges of side effects of the therapy limit the T cell therapy market growth.
定制研究以满足您的需求
我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。
T 细胞治疗市场：
复合年增长率（2022 - 2030 年）16.0％- 2022 年市场规模
27.5 亿美元 - 2030 年市场规模
90.4 亿美元
市场动态
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
关键人物;主力;重要一员
- Immunocore 控股有限公司
- 传奇生物科技公司
- 詹森全球服务有限公司
- 吉利德科学公司
- 百时美施贵宝公司
- 蓝鸟生物公司
- 诺华公司
- JW (开曼) 治疗有限公司
- 笛卡尔治疗公司
区域概况
- 北美
- 欧洲
- 亚太
- 南美洲和中美洲
- 中东和非洲
市场细分
情态- 研究与商业化
治疗类型- CAR-T 细胞疗法和 T 细胞受体
指征- 血液系统恶性肿瘤和实体肿瘤
地理- 北美
- 欧洲
- 亚太地区
- 中东和非洲
- 南美洲和中美洲
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
报告细分和范围：
“全球 T 细胞治疗市场”根据治疗方式、治疗类型和适应症进行细分。根据治疗方式，分为研究和商业化。2022 年，商业化部分占据了更大的市场份额。根据治疗类型，T 细胞市场分为CAR T 细胞治疗和基于 T 细胞受体 (TCR) 的治疗。就适应症而言，T 细胞治疗市场分为血液系统恶性肿瘤和实体肿瘤。根据地理位置，T 细胞治疗市场分为北美（美国、加拿大和墨西哥）、欧洲（法国、德国、意大利、英国、西班牙和欧洲其他地区）、亚太地区（澳大利亚、中国、日本、韩国和亚太其他地区）、中东和非洲（沙特阿拉伯、以色列和中东和非洲其他地区）以及南美洲和中美洲（巴西）。
节段分析：
根据方式，T 细胞治疗市场分为研究和商业化。2022 年，商业化部分占据了最大的市场份额。此外，预计同一部分在预测期内增长最快。产品发布的增加以及对 T 细胞疗法对癌症治疗益处的认识的提高推动了商业化部分的增长。以下是一些用于癌症治疗的商业化产品。
- 2022年，FDA批准了Janssen Biotech, Inc.生产的CARVYKTI，它是一种利用慢病毒改造的自体CAR-T细胞，用于攻击表达BCMA的肿瘤细胞，以治疗某些类型的难治性多发性骨髓瘤。
- 2022年1月，美国FDA批准了Immunocare生产的KIMMTRAK，用于治疗不可切除或转移性葡萄膜黑色素瘤。
根据治疗类型，T 细胞治疗市场分为 CAR T 细胞治疗和基于 T 细胞受体 (TCR) 的治疗。2022 年，CAR T 细胞治疗细分市场占据了更大的市场份额。此外，在预测期内，同一细分市场将以显着的增长率增长。在嵌合抗原受体 (CAR) T 细胞治疗技术中，从患者身上获得的 T 细胞经过人工生物工程改造，以表达能够识别和附着在肿瘤细胞上的 CAR。这些公司正在进行战略发展，例如合作、扩张、协议、伙伴关系以及 CAR T 细胞细分市场中的公司推出新产品，从而推动 T 细胞治疗市场的增长。例如，2022 年，FDA 批准了 Janssen Biotech, Inc. 生产的 CARVYKTI。CARVYKTI 是一种称为 CAR-T 的疗法，代表嵌合抗原受体 T 细胞。 CARVYKTI（ciltacabtagene autoleucel）是一种用于治疗骨髓癌（称为多发性骨髓瘤）的成年患者的药物。CARVYKTI 可治疗已接受过四种或更多种疗法的复发或难治性多发性骨髓瘤成年患者，这些疗法包括蛋白酶体抑制剂、免疫调节剂和抗 CD38单克隆抗体。
根据适应症，T 细胞治疗市场分为血液系统恶性肿瘤和实体肿瘤。2022 年，血液系统恶性肿瘤细分市场占据最大市场份额；预计同一细分市场在预测期内将以显着的增长率增长。血液系统恶性肿瘤是影响人体血液、骨髓和淋巴结的癌症类型。白血病、淋巴瘤、骨髓瘤和骨髓瘤是一些血液系统恶性肿瘤。根据白血病和淋巴瘤协会的数据，到 2023 年，预计美国将有约 184,000 人被诊断出患有白血病、淋巴瘤或骨髓瘤。根据同一来源，美国约有 1,629,000 人患有血液系统恶性肿瘤或处于缓解期。由于全球血液系统恶性肿瘤患病率的增加，治疗方法得到了迅速发展。
区域分析：
根据地理位置，T 细胞治疗市场分为五个主要区域：北美、欧洲、亚太地区、南美和中美以及中东和非洲。北美市场分析主要集中在三个主要国家——美国、加拿大和墨西哥。2022 年，北美占据了最大的 T 细胞治疗市场份额。由于癌症和自身免疫性疾病等慢性疾病负担的增加、研发活动的增长以及强大而成熟的市场参与者，北美的 T 细胞治疗市场预计将增长。此外，随着 CAR T 细胞疗法临床研究的增加，北美市场预计将在预测期内增长。
T 细胞治疗市场机会：
T 细胞疗法投资不断增长
在 T 细胞治疗市场运营的公司专注于战略发展，例如合作、扩张、协议和投资，这些有助于他们提高销售额、扩大地理覆盖范围并增强满足现有客户群需求的能力。下面提到了 T 细胞治疗市场的一些值得注意的发展。
- 2023 年 5 月，交易完成后，Laurus Labs 在 ImmunoACT 的股份将按完全摊薄后增至 33.86%。该公司已于 2021 年 11 月收购了 ImmunoACT 26.62% 的股份。ImmunoACT 拥有一系列处于不同开发阶段的 CAR T 细胞疗法资产，用于治疗多种自身免疫性疾病和肿瘤适应症。这项投资进一步加强了 Laurus Labs 对获取新型细胞和基因治疗技术的承诺，并提高了患者负担得起的价格。这项投资将进一步帮助 ImmunoACT 为生产更多治疗方法做好准备。
- 2023 年 1 月，加州再生医学研究所 (CIRM) 投资 400 万美元开发和测试 CAR T 细胞疗法，用于治疗从淋巴瘤到白血病的各种 B 细胞恶性肿瘤。
- 2021 年 11 月，Autolus Therapeutics plc（一家开发下一代程序化 T 细胞疗法的临床阶段生物制药公司）与 Blackstone Life Sciences 达成合作和融资协议，根据该协议，资金由 Blackstone 管理。Blackstone 提供了高达 2.5 亿美元的股权和产品融资，以支持 Autolus 开发其 CD19 CAR T 细胞研究治疗产品 obecabtagene autoleucel（obe-cel），以及 obe-cel 在 B 细胞恶性肿瘤中的下一代产品疗法。
因此，这些投资在 T 细胞治疗市场创造了有利可图的机会。
T 细胞治疗市场报告范围
| 报告属性 | 细节 |
|---|---|
| 2022 年市场规模 | 27.5亿美元 |
| 2030 年的市场规模 | 90.4 亿美元 |
| 全球复合年增长率（2022 - 2030 年） | 16.0％ |
| 历史数据 | 2020-2021 |
| 预测期 | 2023-2030 |
| 涵盖的领域 | 按方式
|
| 覆盖地区和国家 | 北美
|
| 市场领导者和主要公司简介 |
|
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
竞争格局和重点公司：
全球 T 细胞治疗市场中的一些知名参与者包括 Immunocore Holdings Plc、Legend Biotech Corp、Janssen Global Services LLC、Gilead Sciences Inc、Bristol-Myers Squibb Co、Bluebird Bio Inc、Novartis AG、JW (Cayman) Therapeutics Co Ltd、Cartesian Therapeutics Inc 和 Innovent Biologics Inc。这些公司专注于新技术、现有产品的进步和地域扩张，以满足全球不断增长的消费者需求并增加其专业产品组合的产品范围。这些公司在全球 T 细胞治疗市场实施各种无机和有机开发。以下是一些例子：
- 2023年5月，传奇生物科技股份有限公司宣布，根据CARTITUDE-4研究（NCT04181827）的数据，向欧洲药品管理局（EMA）提交了CARVYKTI的II型变异申请，该研究研究了对已接受过一至三种先前治疗方案的复发和来那度胺难治性多发性骨髓瘤成年患者的治疗。
- 2023年3月，专注于开发、制造和商业化细胞免疫治疗产品的独立创新型生物技术公司JW Therapeutics启动了Carteyva（relmacabtagene autoleucel注射液）用于高危大B细胞淋巴瘤患者一线治疗的临床研究及首例患者输注。
- 2022年6月，美国食品药品监督管理局（FDA）批准了Breyanzi（lisocabtagene maraleucel），一种针对CD19的嵌合抗原受体（CAR）T细胞疗法，用于治疗成人大B细胞淋巴瘤（LBCL）患者，包括未另行指定的弥漫大B细胞淋巴瘤（DLBCL）（包括源自惰性淋巴瘤的DLBCL）、高级别B细胞淋巴瘤、原发性纵隔大B细胞淋巴瘤和3B级滤泡性淋巴瘤。
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The T cell therapy market, based on modality, is bifurcated into research and commercialized. In 2022, the commercialized segment held the largest share of the market. Moreover, same segment is expected to grow at the fastest rate during the coming years.
Asia Pacific is expected to be the fastest growing region in the T cell therapy market. The market in Asia Pacific is expected to witness significant growth as CAR T-cell therapy is efficient in treating cancer, elevating the market growth in the region. Many clinical trials for CAR T-cell therapy are ongoing in the region, offering new opportunities in APAC.
US holds the largest market share in T cell therapy market. The growth of the market in the country is due to the increasing burden of chronic disorders such as cancer and autoimmune disorders, growth in research and development activities, and strong and established market players.
One of the most promising procedures of cancer treatment is T cell therapy, and every year, an increasing number of pre-clinical and clinical research is being conducted to increase its application. CAR T cell therapy has also generated interest among oncologists and academics. Immune checkpoint inhibitors are more common and widely used than CAR T cell treatments, even though CAR T cell therapy demonstrated the same capacity to destroy extremely advanced leukemias and lymphomas and hold the disease away for many years.
The T cell therapy market majorly consists of the players such as Immunocore Holdings Plc, Legend Biotech Corp, Janssen Global Services LLC, Gilead Sciences Inc, Bristol-Myers Squibb Co, Bluebird Bio Inc, Novartis AG, JW (Cayman) Therapeutics Co Ltd, Cartesian Therapeutics Inc, and Innovent Biologics Inc. among others.
The factors that are driving growth of the market are growing burden of cancer worldwide and an increasing number of T cell therapy approvals.
The List of Companies - T Cell Therapy Market
- Immunocore Holdings Plc
- Legend Biotech Corp
- Janssen Global Services LLC
- Gilead Sciences Inc
- Bristol-Myers Squibb Co
- Bluebird Bio Inc
- Novartis AG
- JW (Cayman) Therapeutics Co Ltd
- Cartesian Therapeutics Inc
- Innovent Biologics Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For